Massachusetts, USA-based Amylyx Pharmaceuticals (Nasdaq: AMLX) has announced topline results from the Phase III PHOENIX study.
On Friday, shares in the company were trading at around a fifth of the previous day’s value, as the results showed the study did not meet its primary efficacy endpoint, a measure of efficacy.
There was also no statistical significance seen in secondary endpoints.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze